Huchmed (HKG:0013) appointed Johnny Cheng, its executive director and chief financial officer, as acting chief executive officer, effective immediately, according to a Monday Hong Kong bourse filing.
Cheng assumes the role after CEO Weiguo Su took a medical leave, the filing said.
Su will remain chief scientific officer, with support from Hutchmed's scientific team, to continue its drug research and development programs.